Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of D… Read more
Bristol-Myers Squibb Company (BMY) - Net Assets
Latest net assets as of December 2025: $55.78 Billion USD
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has net assets worth $55.78 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.67 Billion) and total liabilities ($-45.11 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $55.78 Billion |
| % of Total Assets | 522.66% |
| Annual Growth Rate | 3.4% |
| 5-Year Change | -56.74% |
| 10-Year Change | 13.62% |
| Growth Volatility | 45.11 |
Bristol-Myers Squibb Company - Net Assets Trend (1987–2024)
This chart illustrates how Bristol-Myers Squibb Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bristol-Myers Squibb Company (1987–2024)
The table below shows the annual net assets of Bristol-Myers Squibb Company from 1987 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $16.39 Billion | -44.42% |
| 2023-12-31 | $29.48 Billion | -5.25% |
| 2022-12-31 | $31.12 Billion | -13.58% |
| 2021-12-31 | $36.01 Billion | -4.95% |
| 2020-12-31 | $37.88 Billion | -26.72% |
| 2019-12-31 | $51.70 Billion | +265.95% |
| 2018-12-31 | $14.13 Billion | +19.25% |
| 2017-12-31 | $11.85 Billion | -27.53% |
| 2016-12-31 | $16.35 Billion | +13.33% |
| 2015-12-31 | $14.42 Billion | -3.73% |
| 2014-12-31 | $14.98 Billion | -1.66% |
| 2013-12-31 | $15.24 Billion | +11.72% |
| 2012-12-31 | $13.64 Billion | -14.05% |
| 2011-12-31 | $15.87 Billion | +1.46% |
| 2010-12-31 | $15.64 Billion | +5.77% |
| 2009-12-31 | $14.79 Billion | +21.11% |
| 2008-12-31 | $12.21 Billion | +15.58% |
| 2007-12-31 | $10.56 Billion | +5.72% |
| 2006-12-31 | $9.99 Billion | -10.86% |
| 2005-12-31 | $11.21 Billion | +9.86% |
| 2004-12-31 | $10.20 Billion | +4.25% |
| 2003-12-31 | $9.79 Billion | +11.76% |
| 2002-12-31 | $8.76 Billion | -18.44% |
| 2001-12-31 | $10.74 Billion | +16.95% |
| 2000-12-31 | $9.18 Billion | +6.19% |
| 1999-12-31 | $8.64 Billion | +14.11% |
| 1998-12-31 | $7.58 Billion | +4.95% |
| 1997-12-31 | $7.22 Billion | +9.88% |
| 1996-12-31 | $6.57 Billion | +12.85% |
| 1995-12-31 | $5.82 Billion | +2.07% |
| 1994-12-31 | $5.70 Billion | -3.97% |
| 1993-12-31 | $5.94 Billion | -1.33% |
| 1992-12-31 | $6.02 Billion | +3.88% |
| 1991-12-31 | $5.79 Billion | +6.96% |
| 1990-12-31 | $5.42 Billion | +6.57% |
| 1989-12-31 | $5.08 Billion | +2.75% |
| 1988-12-31 | $4.95 Billion | +4.06% |
| 1987-12-31 | $4.75 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bristol-Myers Squibb Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 224.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $14.91 Billion | 91.29% |
| Common Stock | $292.00 Million | 1.79% |
| Other Comprehensive Income | $-1.24 Billion | -7.58% |
| Other Components | $2.37 Billion | 14.50% |
| Total Equity | $16.34 Billion | 100.00% |
Bristol-Myers Squibb Company Competitors by Market Cap
The table below lists competitors of Bristol-Myers Squibb Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Accenture plc
NYSE:ACN
|
$121.95 Billion |
|
S&P Global Inc
NYSE:SPGI
|
$124.01 Billion |
|
British American Tobacco p.l.c.
NYSE:BTI
|
$124.44 Billion |
|
State Bank of India
PINK:SBKFF
|
$125.51 Billion |
|
Stryker Corporation
NYSE:SYK
|
$121.18 Billion |
|
Danaher Corporation
NYSE:DHR
|
$120.38 Billion |
|
Newmont Goldcorp Corp
NYSE:NEM
|
$119.99 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
$119.93 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bristol-Myers Squibb Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,430,000,000 to 16,335,000,000, a change of -13,095,000,000 (-44.5%).
- Net loss of 8,948,000,000 reduced equity.
- Dividend payments of 4,863,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 308,000,000.
- Other factors increased equity by 408,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.95 Billion | -54.78% |
| Dividends Paid | $4.86 Billion | -29.77% |
| Other Comprehensive Income | $308.00 Million | +1.89% |
| Other Changes | $408.00 Million | +2.5% |
| Total Change | $- | -44.50% |
Book Value vs Market Value Analysis
This analysis compares Bristol-Myers Squibb Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 26.82x to 7.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1987-12-31 | $2.23 | $59.71 | x |
| 1988-12-31 | $2.37 | $59.71 | x |
| 1989-12-31 | $2.45 | $59.71 | x |
| 1990-12-31 | $2.60 | $59.71 | x |
| 1991-12-31 | $2.79 | $59.71 | x |
| 1992-12-31 | $2.95 | $59.71 | x |
| 1993-12-31 | $2.88 | $59.71 | x |
| 1994-12-31 | $2.80 | $59.71 | x |
| 1995-12-31 | $2.87 | $59.71 | x |
| 1996-12-31 | $3.23 | $59.71 | x |
| 1997-12-31 | $3.54 | $59.71 | x |
| 1998-12-31 | $3.73 | $59.71 | x |
| 1999-12-31 | $4.26 | $59.71 | x |
| 2000-12-31 | $4.60 | $59.71 | x |
| 2001-12-31 | $5.46 | $59.71 | x |
| 2002-12-31 | $4.34 | $59.71 | x |
| 2003-12-31 | $5.02 | $59.71 | x |
| 2004-12-31 | $5.16 | $59.71 | x |
| 2005-12-31 | $5.65 | $59.71 | x |
| 2006-12-31 | $5.09 | $59.71 | x |
| 2007-12-31 | $5.33 | $59.71 | x |
| 2008-12-31 | $6.12 | $59.71 | x |
| 2009-12-31 | $7.50 | $59.71 | x |
| 2010-12-31 | $9.10 | $59.71 | x |
| 2011-12-31 | $9.29 | $59.71 | x |
| 2012-12-31 | $8.07 | $59.71 | x |
| 2013-12-31 | $9.12 | $59.71 | x |
| 2014-12-31 | $8.89 | $59.71 | x |
| 2015-12-31 | $8.50 | $59.71 | x |
| 2016-12-31 | $9.63 | $59.71 | x |
| 2017-12-31 | $7.11 | $59.71 | x |
| 2018-12-31 | $8.57 | $59.71 | x |
| 2019-12-31 | $30.14 | $59.71 | x |
| 2020-12-31 | $16.75 | $59.71 | x |
| 2021-12-31 | $16.01 | $59.71 | x |
| 2022-12-31 | $14.47 | $59.71 | x |
| 2023-12-31 | $14.16 | $59.71 | x |
| 2024-12-31 | $8.06 | $59.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bristol-Myers Squibb Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.53%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 5.67x
- Recent ROE (-54.78%) is below the historical average (25.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1987 | 22.46% | 14.13% | 1.01x | 1.58x | $592.50 Million |
| 1988 | 25.34% | 14.65% | 1.03x | 1.67x | $759.20 Million |
| 1989 | 14.69% | 8.13% | 1.08x | 1.67x | $238.60 Million |
| 1990 | 32.26% | 16.97% | 1.12x | 1.70x | $1.21 Billion |
| 1991 | 35.48% | 18.42% | 1.19x | 1.62x | $1.48 Billion |
| 1992 | 32.59% | 17.59% | 1.03x | 1.79x | $1.36 Billion |
| 1993 | 32.98% | 17.16% | 0.94x | 2.04x | $1.36 Billion |
| 1994 | 32.29% | 15.37% | 0.93x | 2.26x | $1.27 Billion |
| 1995 | 31.12% | 13.16% | 0.99x | 2.39x | $1.23 Billion |
| 1996 | 43.38% | 18.92% | 1.03x | 2.24x | $2.19 Billion |
| 1997 | 44.40% | 19.19% | 1.12x | 2.07x | $2.48 Billion |
| 1998 | 41.46% | 17.18% | 1.12x | 2.15x | $2.38 Billion |
| 1999 | 48.20% | 20.61% | 1.18x | 1.98x | $3.30 Billion |
| 2000 | 51.32% | 25.86% | 1.04x | 1.91x | $3.79 Billion |
| 2001 | 48.85% | 27.00% | 0.72x | 2.52x | $4.17 Billion |
| 2002 | 24.41% | 11.79% | 0.72x | 2.86x | $1.26 Billion |
| 2003 | 31.74% | 14.87% | 0.76x | 2.80x | $2.13 Billion |
| 2004 | 23.41% | 12.32% | 0.64x | 2.98x | $1.37 Billion |
| 2005 | 26.77% | 15.62% | 0.68x | 2.51x | $1.88 Billion |
| 2006 | 15.86% | 8.85% | 0.70x | 2.56x | $585.90 Million |
| 2007 | 20.50% | 11.19% | 0.74x | 2.48x | $1.11 Billion |
| 2008 | 42.86% | 25.47% | 0.70x | 2.41x | $4.02 Billion |
| 2009 | 71.49% | 56.42% | 0.61x | 2.09x | $9.13 Billion |
| 2010 | 19.74% | 15.92% | 0.63x | 1.98x | $1.53 Billion |
| 2011 | 23.25% | 17.46% | 0.64x | 2.07x | $2.11 Billion |
| 2012 | 14.39% | 11.12% | 0.49x | 2.64x | $597.70 Million |
| 2013 | 16.91% | 15.64% | 0.42x | 2.55x | $1.05 Billion |
| 2014 | 13.49% | 12.62% | 0.47x | 2.27x | $518.80 Million |
| 2015 | 10.97% | 9.45% | 0.52x | 2.23x | $138.40 Million |
| 2016 | 27.55% | 22.94% | 0.58x | 2.08x | $2.84 Billion |
| 2017 | 8.58% | 4.85% | 0.62x | 2.86x | $-167.10 Million |
| 2018 | 35.07% | 21.81% | 0.64x | 2.49x | $3.52 Billion |
| 2019 | 6.66% | 13.15% | 0.20x | 2.52x | $-1.72 Billion |
| 2020 | -23.78% | -21.16% | 0.36x | 3.13x | $-12.78 Billion |
| 2021 | 19.46% | 15.08% | 0.42x | 3.04x | $3.40 Billion |
| 2022 | 20.37% | 13.71% | 0.48x | 3.12x | $3.22 Billion |
| 2023 | 27.27% | 17.83% | 0.47x | 3.23x | $5.08 Billion |
| 2024 | -54.78% | -18.53% | 0.52x | 5.67x | $-10.58 Billion |
Industry Comparison
This section compares Bristol-Myers Squibb Company's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $342,021,917,222
- Average return on equity (ROE) among peers: 19.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $55.78 Billion | 22.46% | -0.81x | $121.36 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |